Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations, Disclosure: Schedules of Discontinued Operations (Details)

Discontinued Operations, Disclosure: Schedules of Discontinued Operations (Details)	3 Months Ended
	Mar. 31, 2016 USD ($)
Details
Expense related to discontinued operations	$ 2,004
Net income (loss) from discontinued operations	$ (2,004)

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details